Previous 10 | Next 10 |
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Exe...
Gainers: BeyondSpring (NASDAQ:BYSI) +151%, Cerus (NASDAQ:CERS) +21%, Novavax (NASDAQ:NVAX) +18%, Global Blood Therapeutics (NASDAQ:GBT) +17%, SCWorx (NASDAQ:WORX) +14%. Losers: Flora Growth (NASDAQ:FLGC) -25%, Arcturus Therapeutics (NASDA...
Rhythm Pharmaceuticals (RYTM -18.3%) has lost more than a tenth in morning hours after the company’s revenue for Q2 2021 lagged analyst estimates on Tuesday. In addition, after the close, the company announced five new mid-stage and late-stage clinical studies for setmelanotide targeti...
Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2021 Results Earnings Conference Call August 3, 2021, 08:00 AM ET Company Participants David Connolly - Head of Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Murray Stewart - Chief Medical ...
The following slide deck was published by Rhythm Pharmaceuticals, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Rhythm Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation
Rhythm Pharmaceuticals (NASDAQ:RYTM): Q2 GAAP EPS of -$0.70 in-line. Revenue of $0.27M misses by $0.28M. Press Release For further details see: Rhythm Pharmaceuticals EPS in-line, misses on revenue
-- Received European Commission authorization of IMCIVREE for treatment of obesity and control of hunger associated with POMC, PCSK1 and LEPR deficiencies -- -- Setmelanotide selected for evaluation as a “Highly Specialised Technology” by Great Britain’s Na...
-- Pivotal Phase 3 EMANATE trial planned in patients with heterozygous POMC, PCSK1 or LEPR, and SRC1 or SH2B1 deficiency obesities -- -- EMANATE, as well as Phase 2 DAYBREAK trial evaluating setmelanotide in 31 new genes, Phase 3 pediatrics trial and Phase 3 trials of weekly setmela...
-- Pamela Cramer appointed Chief Human Resources Officer -- -- Linda Shapiro Manning, M.D., Ph.D., appointed Senior Vice President, Clinical -- BOSTON, July 29, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical compa...
BOSTON, July 28, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced a collaborative research agreement with the Clinical...
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair “Al...
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rar...
2024-06-14 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...